J.W. Cole Advisors Inc. Takes $512,000 Position in Exact Sciences Co. (NASDAQ:EXAS)

J.W. Cole Advisors Inc. purchased a new stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 7,509 shares of the medical research company's stock, valued at approximately $512,000.

A number of other institutional investors also recently bought and sold shares of EXAS. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Exact Sciences by 16.1% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 89,196 shares of the medical research company's stock worth $6,160,000 after acquiring an additional 12,349 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its position in shares of Exact Sciences by 5.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 207,364 shares of the medical research company's stock worth $14,361,000 after purchasing an additional 10,356 shares in the last quarter. Profund Advisors LLC grew its stake in shares of Exact Sciences by 239.8% in the 2nd quarter. Profund Advisors LLC now owns 78,589 shares of the medical research company's stock worth $3,320,000 after buying an additional 55,459 shares during the last quarter. William Blair Investment Management LLC bought a new position in Exact Sciences during the 2nd quarter valued at approximately $163,896,000. Finally, Grandfield & Dodd LLC raised its stake in Exact Sciences by 142.5% during the first quarter. Grandfield & Dodd LLC now owns 55,224 shares of the medical research company's stock valued at $3,814,000 after buying an additional 32,453 shares during the last quarter. 88.82% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Raymond James restated a "market perform" rating on shares of Exact Sciences in a report on Thursday, September 26th. Canaccord Genuity Group lifted their target price on shares of Exact Sciences from $75.00 to $95.00 and gave the stock a "buy" rating in a report on Tuesday. Sanford C. Bernstein increased their price target on shares of Exact Sciences from $75.00 to $90.00 and gave the company an "outperform" rating in a report on Wednesday. Benchmark decreased their price objective on shares of Exact Sciences from $91.00 to $67.00 and set a "buy" rating for the company in a report on Thursday, August 1st. Finally, Wells Fargo & Company assumed coverage on Exact Sciences in a research note on Tuesday, August 27th. They set an "overweight" rating and a $75.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $80.64.

Exact Sciences Stock Performance

NASDAQ:EXAS traded down $1.53 during mid-day trading on Thursday, hitting $68.93. 1,469,998 shares of the company traded hands, compared to its average volume of 2,525,099. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62. The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.73. The firm has a market cap of $12.72 billion, a price-to-earnings ratio of -52.22 and a beta of 1.27. The stock's fifty day moving average price is $66.61 and its 200-day moving average price is $56.61.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The medical research company reported ($0.09) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.28. The business had revenue of $699.26 million during the quarter, compared to analyst estimates of $690.02 million. Exact Sciences had a negative net margin of 6.70% and a negative return on equity of 4.97%. The company's revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the business posted ($0.45) earnings per share. Research analysts anticipate that Exact Sciences Co. will post -0.87 earnings per share for the current fiscal year.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the company's stock in a transaction that occurred on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the completion of the transaction, the executive vice president now directly owns 12,758 shares in the company, valued at $893,060. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.36% of the company's stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.